$AGX

Argan (AGX) reported a $2.5 billion project backlog, driven by demand from data centers and energy developers. Shares rose 43% over the past year, closing at $419.64. The company's Superscore of 77 reflects strong financials, operational efficiency, and revenue growth, but also notes valuation risks and execution challenges. Q2 revenue was $384 million, up 56.5% year-over-year, with a 22% gross margin.

Argan (NYSE:AGX) and MYR Group (NASDAQ:MYRG) are power infrastructure contractors. Argan reported Q3 revenue of $384M, up 61.5%, with net income of $53.3M. It has $1.03B in cash but $440M in working capital. Backlog decreased to $2.52B. Investors should monitor contract awards and project timing. Hedge fund ownership of Argan slightly declined in Q2 2026.

ARGAN reported 9M 2026 rental income of €166.2M, up 5% YoY, with 99.9% occupancy. The company raised its FY26 rental income target to at least €222M, according to a press release.

Argan (AGX) may report stronger H2'27 results due to a new fabrication facility, early completion of a solar project, and increased AI/electrification projects. Despite potential delays from data center moratoriums, the company benefits from multi-year capex trends and a healthy balance sheet. AGX is upgraded to Buy with a $478.40 price target, offering >30% long-term upside, but investors should be cautious of technical weakness and elevated short interest.

Argan (AGX) raised its quarterly dividend by 40% to $0.70 per share. The stock has seen recent volatility, down 22.3% in the past month but up 50.3% over one year. Analysts debate its valuation, with some seeing it as undervalued at $389.85, while others caution about its high P/E ratio of 30.5x.

Argan (AGX) raised its dividend by 40% and expanded its share-repurchase program. The company completed several power projects and acquired ValCor Communications. Analysts expect earnings growth and have raised price targets, with a consensus 'Moderate Buy' rating.

Argan (AGX) reported record Q2 revenue of $384.0M (+61.5% YoY) and net income of $53.3M, driven by its Power segment. Gross margin slipped to 19.3%, and backlog decreased to $2.5B. The company is debt-free with $1.03B in cash, returning $51.7M to shareholders. Management expects new projects but faces regulatory challenges and margin compression.

Zacks upgraded five stocks to Strong Buy: RCM Technologies (RCMT), Healthcare Services Group (HCSG), Bloomin' Brands (BLMN), Argan (AGX), and Globus Medical (GMED). Their earnings estimates rose 13.3%, 12.9%, 10.1%, 6.7%, and 5.3% respectively in 60 days.

Argan (AGX) stock fell 8% after Piper Sandler analyst Dimple Gosai initiated coverage with an underweight rating and a $273 price target, citing capacity limits and a potential peak in project awards.

Argan (AGX) reported Q2 2027 revenue of $384.0M, up 61.5%, with net income of $53.3M ($3.76 per diluted share). Power segment revenue grew 53% YoY to $301M, while Industrial segment revenue rose 111% to $76M. Consolidated backlog decreased to $2.5B. The company plans to complete a new fabrication facility in North Carolina by Q3 2027.